China is aiming to take the global lead in a promising biotech area by setting its first national standards for ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
AFP on MSN2d
China head of pharmaceutical giant AstraZeneca detained after reports of probe into illegal drug importsPharmaceutical giant AstraZeneca has confirmed that Leon Wang, the head of its China operations, had been detained.
The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country into the company’s ...
California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China-based Leads ...
American venture capitalists are increasingly building U.S.-based companies from scratch to commercialize drugs developed in ...
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...
Bayer and Codone Biotechnology (Codone) signed a collaboration agreement, marking Codone the first resident company of Bayer ...
The Wall Street Journal on MSN8d
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain PartnersU.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...
Pfizer (PFE, Financials) announced plans to invest $1 billion in China over the next five years to enhance research and ...
AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...
With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback